SK Biopharm Signs Pharmaceutical Contract Worth 10.3 Billion KRW with Subsidiary
[Asia Economy Reporter Hwang Yoon-joo] SK Biopharm announced on the 21st that it has signed a pharmaceutical supply contract worth 10,380,620,000 KRW with its subsidiary SK Life Science. This accounts for 39.93% of recent sales revenue. The contract period is from March 21, 2022, to June 30, 2022.
Hot Picks Today
!["It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]](https://cwcontent.asiae.co.kr/asiaresize/93/2026052019230771274_1779272587.jpg)
"It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
